Dialysis Clinic, Inc, Nashville, TN.
Duke University School of Medicine, Durham, NC.
Am J Kidney Dis. 2020 Dec;76(6):868-876. doi: 10.1053/j.ajkd.2020.07.021. Epub 2020 Sep 10.
Medication-related problems are a leading cause of morbidity and mortality. Patients requiring dialysis are at heightened risk for adverse drug reactions because of the prevalence of polypharmacy, multiple chronic conditions, and altered (but not well understood) medication pharmacokinetics and pharmacodynamics inherent to kidney failure. To minimize preventable medication-related problems, health care providers need to prioritize medication safety for this population. The cornerstone of medication safety is medication reconciliation. We present a case highlighting adverse outcomes when medication reconciliation is insufficient at care transitions. We review available literature on the prevalence of medication discrepancies worldwide. We also explain effective medication reconciliation and the practical considerations for implementation of effective medication reconciliation in dialysis units. In light of the addition of medication reconciliation requirements to the Centers for Medicare & Medicaid Services End-Stage Renal Disease Quality Incentive Program, this review also provides guidance to dialysis unit leadership for improving current medication reconciliation practices. Prioritization of medication reconciliation has the potential to positively affect rates of medication-related problems, as well as medication adherence, health care costs, and quality of life.
药物相关问题是发病率和死亡率的主要原因。需要透析的患者由于普遍存在的多种药物治疗、多种慢性疾病以及与肾衰竭相关的(但尚未充分理解)改变的药物药代动力学和药效动力学,易发生药物不良反应。为了最大限度地减少可预防的药物相关问题,医疗保健提供者需要将药物安全性作为这一人群的首要任务。药物安全性的基石是药物重整。我们提出了一个案例,重点介绍了在护理交接时药物重整不足时的不良后果。我们回顾了全球药物差异的流行程度的现有文献。我们还解释了有效的药物重整,以及在透析单位实施有效的药物重整的实际考虑因素。鉴于药物重整要求已被添加到医疗保险和医疗补助服务中心终末期肾脏疾病质量激励计划中,因此本次审查还为改善当前药物重整实践提供了透析单位领导层的指导。优先进行药物重整有可能积极影响药物相关问题的发生率、药物依从性、医疗保健成本和生活质量。